# Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

> **NCT07191379** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Odense University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **OTHER:** The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting.

## Key facts

- **NCT ID:** NCT07191379
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191379, "Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07191379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*